Ríos-Pohl Loreto, Franco Macarena, Navea Daniel, Venegas Viviana, Cerda Tomás
Epilepsia, Clinica Integral de Epilepsia Infanto-Juvenil, Santiago, Chile.
Pediatric Neurology, Hospital San Pablo, Coquimbo, Chile.
Epilepsia Open. 2024 Dec;9(6):2546-2552. doi: 10.1002/epi4.13081. Epub 2024 Nov 6.
The purpose of this study is to analyze composition of HMS (homemade CBD), NLS (non-licensed commercial products), and bioequivalent CBD (BES) collected from Chilean patients that voluntary accepted to analyze the "CBD-substance."
Samples were collected through an open invitation for different patients to anonymously and free of charge participate in the analysis of CBD oil. The analysis of the active principle was performed using High-Resolution Liquid Chromatography (HPLC).
A total of 35 samples were collected between March 2020 and September 2021, including two BES, six NLS, and 27 HMS products. The BES had an average CBD concentration of 89.15 mg/mL and an average THC concentration of 0.015 mg/mL, which complied with the maximum THC levels required by regulatory authorities (<0.2% THC.). The NLS (six samples) exhibited significant variability in CBD concentrations, ranging from a maximum of 78.5 mg/mL to a minimum of 0.1 mg/mL, with an average of 25.41 mg/mL. The THC concentrations ranged from 0 mg/mL to 2.43 mg/mL with an average of 0.62 mg/mL. The HMS products exhibited even higher variations of CBD concentrations, ranging from 0 to a maximum of 6.6 mg/mL. THC concentrations were even more variable, ranging from 0 mg/mL to 388 mg/mL.
The medical community and patients involved should be aware that Hemp products are not pure and/or innocuous. HMS are likely to have high levels of THC and very low CBD, far away from therapeutic doses of CBD. CBD used in epilepsy should be restricted to licensed products, especially in children where THC toxicity is much more harmful.
The study analyzed three types of CBD (cannabidiol) oils: homemade, non-licensed, and bioequivalent. Homemade and non-licensed products showed nonacceptable variance of CBD and THC concentration (tetrahydrocannabinol), in some cases with 0 mgs of CBD and many beyond THC maximum accepted. The THC is another component found in cannabis and is responsible for the neurotoxic effects. Only bioequivalent products showed concentrations of CBD and THC acceptable for epilepsy treatment, therefore are the only products recommended for such purpose.
本研究旨在分析从自愿接受“CBD物质”分析的智利患者中收集的自制CBD（HMS）、非许可商业产品（NLS）和生物等效CBD（BES）的成分。
通过公开邀请不同患者免费匿名参与CBD油分析来收集样本。使用高效液相色谱法（HPLC）对活性成分进行分析。
在2020年3月至2021年9月期间共收集了35个样本，包括2个BES、6个NLS和27个HMS产品。BES的CBD平均浓度为89.15毫克/毫升，THC平均浓度为0.015毫克/毫升，符合监管机构要求的THC最高水平（<0.2% THC）。NLS（6个样本）的CBD浓度存在显著差异，范围从最高78.5毫克/毫升到最低0.1毫克/毫升，平均为25.41毫克/毫升。THC浓度范围从0毫克/毫升到2.43毫克/毫升，平均为0.62毫克/毫升。HMS产品的CBD浓度变化更大，范围从0到最高6.6毫克/毫升。THC浓度变化甚至更大，范围从0毫克/毫升到388毫克/毫升。
医学界和相关患者应意识到大麻产品并非纯净和/或无害。HMS可能含有高水平的THC和极低的CBD，远低于CBD的治疗剂量。用于癫痫治疗的CBD应限于许可产品，尤其是在儿童中，因为THC毒性危害更大。
该研究分析了三种类型的CBD（大麻二酚）油：自制的、非许可的和生物等效的。自制和非许可产品的CBD和THC（四氢大麻酚）浓度存在不可接受的差异，在某些情况下CBD含量为0毫克，许多产品超出了THC的最大可接受量。THC是大麻中的另一种成分，会导致神经毒性作用。只有生物等效产品的CBD和THC浓度可用于癫痫治疗，因此是唯一推荐用于此目的的产品。
